Interested in discontinuing your GLP-1 due to side effects, cost or other concerns?
Learn about upcoming clinical trials for potential new medications to help you maintain weight loss and let you stop taking a GLP-1 treatment like tirzepatide or semaglutide (Wegovy®, Ozempic®, Rybelsus®, Zepbound® or Mounjaro®). Study-related care may be provided at no cost, with compensation for time and travel.
Space is limited—apply today to see if you qualify.
You may be eligible if you:
- Are between 18 and 75 years of age
- Have been taking a weekly dose of a brand name GLP-1 (semaglutide or tirzepatide) continuously for more than 6 months
- Had a documented BMI of at least 30 kg/m2 before starting your GLP-1
- Have lost at least 10% of your body weight since starting your GLP-1
- Are willing to discontinue use of your GLP-1 during the study
There are other requirements for taking part in this clinical trial. The study team will explain these to you if you’d like to learn more.
Qualified Participants May:
- Receive compensation for time and travel
- See a study doctor at no cost
- Receive access to study medications
Participation is voluntary, and health insurance is not required.
Study Location:
These studies are taking place in Stamford, CT and Bridgeport, CT.
How to Apply:
Submit your information using our form on the right side of this page. A member of our friendly team will reach out to discuss next steps and answer your questions.
Research Study:
Maintaining Weight Loss After Discontinuing a GLP-1
Compensation
May be available for time and travel for those who qualify. No cost to participate. Health insurance not required.
Eligible Ages
Open to adults aged 18 – 80.